Exscientia Future Growth
Future criteria checks 1/6
Exscientia's earnings are forecast to decline at 4.3% per annum while its annual revenue is expected to grow at 7.3% per year. EPS is expected to decline by 1.8% per annum. Return on equity is forecast to be -19% in 3 years.
Key information
-4.3%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs earnings growth | 35.4% |
| Revenue growth rate | 7.3% |
| Future return on equity | -19.0% |
| Analyst coverage | Low |
| Last updated | 03 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 43 | N/A | N/A | N/A | 2 |
| 12/31/2025 | 35 | -138 | N/A | N/A | 3 |
| 12/31/2024 | 26 | -132 | N/A | N/A | 3 |
| 6/30/2024 | 21 | -130 | -112 | -100 | N/A |
| 3/31/2024 | 20 | -129 | -122 | -105 | N/A |
| 12/31/2023 | 20 | -146 | -144 | -118 | N/A |
| 9/30/2023 | 24 | -144 | -195 | -166 | N/A |
| 6/30/2023 | 22 | -148 | -205 | -173 | N/A |
| 3/31/2023 | 26 | -141 | -119 | -88 | N/A |
| 12/31/2022 | 27 | -119 | -83 | -61 | N/A |
| 9/30/2022 | 25 | -100 | -46 | -28 | N/A |
| 6/30/2022 | 36 | -69 | 3 | 17 | N/A |
| 3/31/2022 | 29 | -59 | -23 | -13 | N/A |
| 12/31/2021 | 27 | -49 | -14 | -7 | N/A |
| 9/30/2021 | 27 | -36 | -7 | 0 | N/A |
| 6/30/2021 | 10 | -39 | -15 | -11 | N/A |
| 3/31/2021 | 13 | -24 | -31 | -27 | N/A |
| 12/31/2020 | 10 | -22 | -24 | -21 | N/A |
| 12/31/2019 | 9 | -6 | 5 | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0RK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0RK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0RK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0RK's revenue (7.3% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 0RK's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0RK is forecast to be unprofitable in 3 years.